- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Suven Life Sciences Limited — Updates, 04-06-2026: Press Release
04-06-2026 | 10:54 am
04-06-2026 | 10:54 am
Suven Life Sciences' Masupirdine Phase 3 study for Alzheimer's agitation received positive DSMB safety review and interim analysis, greenlighting trial continuation without changes. Enrollment is 88% complete, on track for early completion, anticipating top-line results in Q2.
No comments yet. Be the first to comment!